- Alexion (NASDAQ:ALXN) owners will receive $60 per share in cash and 2.1243 ADS of AstraZeneca (NASDAQ:AZN) for each share of Alexion they own. Based on AZN's recent closing price, that implies a deal value of $39B, or $175 per share. That's about a 45% premium to Alexion's close on Friday.
- Alexion's leading expertise in complement biology will accelerate AstraZeneca's growing presence in immunology, say the companies. The deal is expected to be immediately accretive to core earnings.
- Conference call. Presentation slides are here.
- https://seekingalpha.com/news/3643887-astrazeneca-buying-alexion-in-39b-cash-and-stock-deal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.